Cardiovascular disease is the number one cause of morbidity and mortality in people with type 2 diabetes. We also know that cardiovascular disease and chronic kidney disease are inextricably linked.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Pharma giants are sweating on the results of a federal government request for guidance on adding weight loss drugs to the ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Every year, over 3,00,000 infants are born with Sickle Cell Disease (SCD) worldwide ... to Action”, led by Hindustantimes.com and HealthShots in partnership with Novo Nordisk India. Flagged off on ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs ...